Evaluación de la duración y el riesgo de sangrado entre diferentes estrategias antiplaquetarias duales administradas después de una intervención coronaria percutánea: una revisión de alcance

Autores/as

DOI:

https://doi.org/10.33448/rsd-v12i8.42867

Palabras clave:

Terapia antiplaquetaria doble; Inhibidores de agregación plaquetaria; Hemorragia.

Resumen

Los pacientes con Síndrome Coronario Agudo (SCA) requieren la implantación de stents liberadores de fármacos tras una intervención coronaria percutánea (ICP), asociado a la administración de terapia antiplaquetaria dual (TDAP) para reducir el riesgo trombótico. Considerando la evaluación entre la protección isquémica y la posibilidad de eventos hemorrágicos, se han utilizado nuevas estrategias TDAP, que permiten la prevención de posibles resultados perjudiciales. El presente estudio tiene como objetivo evaluar la duración y el riesgo de sangrado entre diferentes estrategias de TDAP administradas después de la ICP. Para esta revisión de alcance, realizada a través de las plataformas PubMed y ScienceDirect, entre los años 2020 y 2023, los descriptores elegidos fueron: ''Inhibidores de la agregación plaquetaria'', ''Intervención coronaria percutánea'' y ''Hemorragia''. Los criterios de inclusión consistieron en (1) evaluación de la duración y el riesgo de sangrado en diferentes estrategias de TDAP (2) análisis entre diferentes tipos de agentes antiplaquetarios (3) estudios que abordaron el seguimiento y el manejo clínico (4) artículos en inglés y portugués. Los criterios de exclusión consistieron en inadecuación al tema, relatos de casos, editoriales, reseñas simples, estudios en animales, además de textos fuera del límite de tiempo. Los regímenes de TDAP prolongados y de acción prolongada mostraron una mayor protección isquémica y un mayor riesgo de hemorragia. Los regímenes de corta o muy corta duración se asociaron con tasas reducidas de hemorragia mayor, siendo beneficiosos para los pacientes de edad avanzada o con trombocitopenia. El manejo de los casos con alto riesgo trombótico y hemorrágico, así como el uso de puntajes predictivos siguen siendo temas controvertidos por dilucidar a través de nuevos estudios.

Citas

Abusnina, W., Baral, N., Seri, A., Ben-Dor, I., Alkhouli, M., Monteleone, P., & Paul, T. K. (2022). Safety and Efficacy of Ultra Short-Duration Dual Antiplatelet Therapy After Percutaneous Coronary Interventions: A Meta analysis of Randomized Controlled Trials. Curr Probl Cardiol, 101295.

Al-Abdouh, A., Barbarawi, M., Abusnina, W., Amr, M., Zhao, D., Savji, N., & Michos, E. D. (2020). Prasugrel v s Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cardiovasc Revasc Med., 21(12), 1613-1618.

Apostolos, A., Chlorogiannis, D., Vasilagkos, G., Katsanos, K., Toutouzas, K., Aminian, A., & Tsigkas, G. (2023). Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta-analysis. Hell. J. Cardiol.

Bajraktari, G., Bytyçi, I., Bajraktari, A., & Henein, M. Y. (2022). Non-inferiority of 1 month versus longer dual antiplatelet therapy in patients undergoing PCI with drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Ther. Adv. Chronic Dis., 13, 20406223221093758.

Benenati, S., Galli, M., De Marzo, V., Pescetelli, F., Toma, M., Andreotti, F., & Porto, I. (2021). Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Euro Heart J Cardiovasc Pharmacother., 7(2), 86-93.

Bhattarai, M., Ibrahim, A. M., Salih, M., Tandan, N., Al-Akchar, M., Ayan, M., & Hafiz, A. M. (2020). Comprehensive Outcomes Evaluation After Percutaneous Coronary Intervention in Stable Ischemic Heart Disease and Acute Coronary Syndrome for Short-Versus Standard-Term Dual Antiplatelet Therapy: A Systematic Review and Meta-analysis of Randomized Control Trials. J Cardiovasc Pharmacol., 76(5), 574-583.

Bianco, M., D'ascenzo, F., Roubin, S. R., Kinnaird, T., Peyracchia, M., Ariza-Solé, A., & Valgimigli, M. (2020). Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int. J. Cardiol., 301, 200-206.

Boudreau, R., Fu, A. Y., Barry, Q. S., Clifford, C. R., Chow, A., Tran, U., & CAPITAL Investigators. (2021). Outcomes in Patients Stratified by PRECISE-DAPT Versus DAPT Scores After Percutaneous Coronary Interventions. Am. J. Cardiol., 161, 19-25.

Brant, L. C., & Passaglia, L. G. (Eds.). (2022). Alta Mortalidade por Infarto Agudo do Miocárdio na América Latina e Caribe: Defendendo a Implementação de Linha de Cuidado no Brasil. Arq. Bras. Cardiol., 119(6), 979-980.

Cesaro, A., Gragnano, F., Calabrò, P., Moscarella, E., Santelli, F., Fimiani, F., & Gugliemini, G. (2021). Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. Int. J. Cardiol., 345, 7-13.

Cho, S., Kang, D. Y., Kim, J. S., Park, D. W., Kim, I. S., Kang, T. S., & Park, S. J. (2023). Dual antiplatelet therapy after percutaneous coronary intervention for left main coronary artery disease. Rev Esp Cardiol., 76(4), 245-252.

Clifford, C. R., Boudreau, R., Visintini, S., Orr, N., Fu, A. Y., Malhotra, N., & So, D. Y. (2022). The association of PRECISE-DAPT score with ischaemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis. Euro Heart J Cardiovasc Pharmacother, 8(5), 511-518.

Costa, F., Montalto, C., Branca, M., Hong, S. J., Watanabe, H., Franzone, A., & Valgimigli, M. (2023). Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. Euro Heart J, 44(11), 954-968.

Costa, F., van Klaveren, D., Colombo, A., Feres, F., Räber, L., Pilgrim, T., & PRECISE-DAPT Study Investigators. (2020). A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. Am. Heart J., 223, 44-47.

Elliott, J., Kelly, S. E., Bai, Z., Skidmore, B., Boucher, M., So, D., & Wells, G. A. (2023). Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis. Can. Med. Assoc. J., 11(1), E118-E130.

Garg, A., Rout, A., Farhan, S., Waxman, S., Giustino, G., Tayal, R., & Rao, S. V. (2022). Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta-analysis. Am. Heart J., 250, 1-10.

Guan, J., Song, W., He, P., Fan, S., Zhi, H., & Wang, L. (2020). Comparative Efficacy and Safety of Duration of Dual Antiplatelet Therapy in Patients with CAD Undergoing Drug-eluting Stent Implantation: A Systematic Review and Network Meta-analysis. Curr. Pharm. Des., 26(44), 5739-5745.

Han, Y., Yuan, X., Hu, X., Fang, Y., Jiang, M., Feng, H., & Gao, L. (2022). Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis. Cardiol. J..

Hu, X., Zhao, W., Zhang, Q., Hu, H., & Luo, S. (2021). Efficacy and Safety of Aspirin Combined with Low-Dose P2Y12 Receptor Antagonists in East Asian Patients Undergoing PCI A Meta-Analysis. Int. Heart J., 62(4), 742-751.

Kedhi, E., Verdoia, M., Suryapranata, H., Damen, S., Camaro, C., Benit, E., & De Luca, G. (2021). Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. Atherosclerosis., 321, 39-44.

Khan, S. U., Singh, M., Valavoor, S., Khan, M. U., Lone, A. N., Khan, M. Z., & Bhatt, D. L. (2020). Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circ., 142(15), 1425-1436

Kheiri, B., Simpson, T. F., Osman, M., Golwala, H., Radaideh, Q., Kumar, K., & Zahr, F. (2020). Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. J. Thromb. Thrombolysis, 50, 867-873.

Kuno, T., Ueyama, H., Takagi, H., Fox, J., & Bangalore, S. (2021). Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: insights from a network meta-analysis of randomized trials. Cardiovasc. Revascularization Med., 28, 50-56.

Kwok, C. S., Wong, C. W., Nagaraja, V., & Mamas, M. A. (2020). A systematic review of the studies that evaluate the performance of the DAPT score. Int. J. Clin. Pract., 74(10), e13591.

Landi, A., Heg, D., Frigoli, E., Vranckx, P., Windecker, S., Siegrist, P., & MASTER DAPT Investigators. (2023). Abbreviated or standard antiplatelet therapy in HBR patients: final 15-month results of the MASTER-DAPT trial. Cardiovasc. Interv., 16(7), 798-812.

Li, J., Qiu, H., Yan, L., Guo, T., Wang, Y., Li, Y., & Gao, R. (2020). Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention. Curr. Med. Res. Opin., 36(11), 1739-1745.

Liu, D., Li, Y. Z., Wu, H., Yang, J., Yang, J., Ding, J. W., & Yang, C. J. (2020). Duration of dual antiplatelet therapy after percutaneous coronary intervention with implantation of second-generation drug-eluting stent: A meta-analysis of randomized controlled trials. Int. J. Pharm. Sci., 75(4), 113-117.

Long, M., Ye, Z., Zheng, J., Chen, W., & Li, L. (2020). Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis. BMC Pharmacol. Toxicol., 21, 1-16.

Montalto, C., Costa, F., Leonardi, S., Micari, A., Oreglia, J. A., Vranckx, P., & Valgimigli, M. (2023). Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials. Eur. Heart J. Cardiovasc. Pharmacother., 9(3), 220-230.

Nicolau, J. C., Feitosa Filho, G. S., Petriz, J. L., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., & Mathias Júnior, W. (2021). Diretrizes da Sociedade Brasileira de Cardiologia sobre angina instável e infarto agudo do miocárdio sem supradesnível do segmento ST–2021. Arq. Bras. Cardiol, 117, 181-264.

Parfrey, S., Abdelrahman, A., Blackman, D., Blaxill, J. M., Cunnington, M. S., Greenwood, J. P., & Bulluck, H. (2022). Safety and efficacy of interrupting dual antiplatelet therapy one month following percutaneous coronary intervention: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 22(1), 1-11.

Park, D. Y., An, S., Kumar, A., Malhotra, S., Jolly, N., Kaur, A., & Vij, A. (2022). Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis. Am J. Cardiovasc Drugs., 22(6), 633-645.

Park, D. Y., Wang, P., An, S., Grimshaw, A. A., Frampton, J., Ohman, E. M., & Nanna, M. G. (2022). Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis. Am. Heart J., 251, 101-114.

Pufulete, M., Harris, J., Pouwels, K., Reeves, B. C., Lasserson, D., Loke, Y. K., & Johnson, T. W. (2022). Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a ‘target trial’. Open Heart., 9(2), e001999.

Rout, A., Sharma, A., Ikram, S., & Garg, A. (2023). Short‐term dual antiplatelet therapy for 1–3 months after percutaneous coronary intervention using drug eluting stents: A systematic review and meta‐analysis of randomized clinical trials. Catheter. Cardiovasc. Interv., 101(2), 299-307.

Samuelsen, P. J., Eggen, A. E., Steigen, T., Wilsgaard, T., Kristensen, A., Skogsholm, A., & Bønaa, K. H. (2021). Incidence and risk factors for major bleeding among patients undergoing percutaneous coronary intervention: Findings from the Norwegian Coronary Stent Trial (NORSTENT). PLoS One, 16(3), e0247358.

Selvaraj, V., Chatterjee, S., Hirai, T., Abbott, J. D., & Bavishi, C. (2022). Three versus 12‐month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta‐analysis of randomized controlled trials. Catheter. Cardiovasc. Interv., 100(7), 1151-1158.

Sheng, X. Y., An, H. J., He, Y. Y., Ye, Y. F., Zhao, J. L., & Li, S. (2022). High‐Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta‐Analysis of Randomized Trials. J. Clin. Pharm. Ther., 47(8), 1112-1121.

Sidhu, M. S., Lyubarova, R., Bangalore, S., & Bonaca, M. P. (2022). Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. Am. Heart J., 246, 44-64.

Silva, M. P. B., Lima, E. R., Borges, P. R. P., Máximo, L. W. M., de Sousa, M. V. A., Leite, A. C., & Dutra, Í. W. (2020). Intervenções de emergência ao paciente com suspeita de infarto agudo do miocárdio. RSD, 9(9), e781997949-e781997949.

Subhaharan, D., Mridha, N., & Singh, K. (2020). Clinical benefits of prolonged dual antiplatelet therapy following complex percutaneous coronary intervention. Coron. Artery Dis., 31(3), 273-278.

Tritschler, T., Patel, A., Kraaijpoel, N., Bhatt, D. L., De Luca, G., Di Santo, P., & Castellucci, L. A. (2022). Case‐fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta‐analysis. Res. Practice Tromb. Haemost., 6(7), e12834.

Tsigkas, G., Apostolos, A., Chlorogiannis, D. D., Bousoula, E., Vasilagkos, G., Tsalamandris, S., & Davlouros, P. (2023). Thirty-Days versus Longer Duration of Dual Antiplatelet Treatment after Percutaneous Coronary Interventions with Newer Drug-Eluting Stents: A Systematic Review and Meta-Analysis. Life, 13(3), 666.

Tsigkas, G., Apostolos, A., Trigka, A., Chlorogiannis, D., Katsanos, K., Toutouzas, K., & Davlouros, P. (2023). Very short versus longer dual antiplatelet treatment after coronary interventions: A systematic review and meta-analysis. Am. J. Cardiovasc. Drugs, 23(1), 35-46.

Valgimigli, M., Cao, D., Angiolillo, D. J., Bangalore, S., Bhatt, D. L., Ge, J., & XIENCE 90 and XIENCE 28 Investigators. (2021). Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI. J. Am. Coll. Cardiol., 78(21), 2060-2072.

Valgimigli, M., Cao, D., Makkar, R. R., Bangalore, S., Bhatt, D. L., Angiolillo, D. J., & Mehran, R. (2021). Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. Am. Heart J., 231, 147-156.

Valgimigli, M., Frigoli, E., Heg, D., Tijssen, J., Jüni, P., Vranckx, P., & Smits, P. C. (2021). Dual antiplatelet therapy after PCI in patients at high bleeding risk. N. Engl. J. Med., 385(18), 1643-1655.

Valgimigli, M., Smits, P. C., Frigoli, E., Bongiovanni, D., Tijssen, J., Hovasse, T., & MASTER DAPT Investigators. (2022). Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur. Heart J., 43(33), 3100-3114.

Verdoia, M., Suryapranata, H., Damen, S., Camaro, C., Benit, E., Barbieri, L., & De Luca, G. (2021). Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial. J. Thromb. Thrombolysis, 1-11.

Watanabe, H., Domei, T., Morimoto, T., Natsuaki, M., Shiomi, H., Toyota, T., & STOPDAPT-2 investigators. (2021). Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. Cardiovasc. Interv. Ther., 36, 91-103.

Witberg, G., Zusman, O., Bental, T., Plakht, I., Gabbay, H., Gerber, Y., & Kornowski, R. (2020). Validation of the DAPT score in real-world patients undergoing coronary stent implantation. Int. J. Cardiol., 300, 99-105.

Xu, Y., Shen, Y., Chen, D., Zhao, P., & Jiang, J. (2021). Efficacy and safety of dual antiplatelet therapy in patients undergoing coronary stent implantation: A systematic review and network meta-analysis. J. Interv. Cardiol., 2021, 1-12.

Zahid, M. B. A., Memon, M. S., Tappiti, M., Kumar, V. S., Nazir, A. M., Koganti, B., & Zahid, M. B. A. (2021). Duration of dual antiplatelet therapy after stent implantation, still an enigma: a systematic review of randomized clinical trials. Cureus, 13(11).

Zhang, J., Chen, Z., Li, C., Wang, D., He, S., Luo, C., & He, Y. (2022). Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Coron. Artery Dis., 33(7), 580-589.

Zhang, W. J., Qiao, X., Liang, X. Y., Li, Y., Yang, R. R., & Wang, Z. L. (2021). Efficacy and safety of short-term 1–3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. Platelets, 32(5), 582-590.

Zhong, P. Y., Shang, Y. S., Bai, N., Ma, Y., Niu, Y., & Wang, Z. L. (2021). Efficacy and safety of very short-term dual antiplatelet therapy after drug-eluting stents implantation for acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials. Front. Cardiovasc. Med., 8, 660360.

Descargas

Publicado

17/08/2023

Cómo citar

SANTOS, T. L. .; PARREIRA, W. da S. P. .; FRACARO, A. C.; CAMPOS, D. R. .; PAVONI, B. de C. .; BEZERRA NETO, P. D. .; SADY, L. M. da R. .; PINHO, L. A. de .; PEREIRA, L. F. B. . Evaluación de la duración y el riesgo de sangrado entre diferentes estrategias antiplaquetarias duales administradas después de una intervención coronaria percutánea: una revisión de alcance. Research, Society and Development, [S. l.], v. 12, n. 8, p. e7112842867, 2023. DOI: 10.33448/rsd-v12i8.42867. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/42867. Acesso em: 23 nov. 2024.

Número

Vol. 12 Núm. 8

Sección

Ciencias de la salud

Licencia

Derechos de autor 2023 Trinnye Luizze Santos; Walquiria da Silva Pedra Parreira; Augusto Cesar Fracaro; Davi Resende Campos; Bianca de Campos Pavoni; Pedro Dias Bezerra Neto; Louise Mota da Rocha Sady; Lênio Airam de Pinho; Lucas França Belfort Pereira

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

Los autores que publican en esta revista concuerdan con los siguientes términos:

1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.

2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.

3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.